Are Performance Measures for Inflammatory Bowel Disease Being Followed? A Large Urban Medical Center Experience

2015 ◽  
Vol 110 ◽  
pp. S781-S782
Author(s):  
Andrew Dikman ◽  
Benjamin Barbash ◽  
Sonya Dasharathy ◽  
Michael Poles ◽  
Lisa Malter
Keyword(s):  
Inflammatory Bowel Disease ◽  
Performance Measures ◽  
Bowel Disease ◽  
Medical Center ◽  
Inflammatory Bowel

scholarly journals Development of Machine Learning Model to Predict the 5-Year Risk of Starting Biologic Agents in Patients with Inflammatory Bowel Disease (IBD): K-CDM Network Study

2020 ◽  
Vol 9 (11) ◽  
pp. 3427 ◽  
Author(s):  
Youn I Choi ◽  
Sung Jin Park ◽  
Jun-Won Chung ◽  
Kyoung Oh Kim ◽  
Jae Hee Cho ◽  
...  
Keyword(s):  
Machine Learning ◽  
Inflammatory Bowel Disease ◽  
Validation Study ◽  
Bowel Disease ◽  
Medical Center ◽  
External Validation ◽  
Biologic Agents ◽  
Risk Level ◽  
Common Data Model ◽  
Inflammatory Bowel

Background: The incidence and global burden of inflammatory bowel disease (IBD) have steadily increased in the past few decades. Improved methods to stratify risk and predict disease-related outcomes are required for IBD. Aim: The aim of this study was to develop and validate a machine learning (ML) model to predict the 5-year risk of starting biologic agents in IBD patients. Method: We applied an ML method to the database of the Korean common data model (K-CDM) network, a data sharing consortium of tertiary centers in Korea, to develop a model to predict the 5-year risk of starting biologic agents in IBD patients. The records analyzed were those of patients diagnosed with IBD between January 2006 and June 2017 at Gil Medical Center (GMC; n = 1299) or present in the K-CDM network (n = 3286). The ML algorithm was developed to predict 5- year risk of starting biologic agents in IBD patients using data from GMC and externally validated with the K-CDM network database. Result: The ML model for prediction of IBD-related outcomes at 5 years after diagnosis yielded an area under the curve (AUC) of 0.86 (95% CI: 0.82–0.92), in an internal validation study carried out at GMC. The model performed consistently across a range of other datasets, including that of the K-CDM network (AUC = 0.81; 95% CI: 0.80–0.85), in an external validation study. Conclusion: The ML-based prediction model can be used to identify IBD-related outcomes in patients at risk, enabling physicians to perform close follow-up based on the patient’s risk level, estimated through the ML algorithm.

scholarly journals QuantiFERON-TB Gold Test Conversion Is Associated with Active Tuberculosis Development in Inflammatory Bowel Disease Patients Treated with Biological Agents: An Experience of a Medical Center in Taiwan

2019 ◽  
Vol 2019 ◽  
pp. 1-9 ◽  
Author(s):  
Hsiang-Chun Lai ◽  
Chia-Hsi Chang ◽  
Ken-Sheng Cheng ◽  
Tsung-Wei Chen ◽  
Yuan-Yao Tsai ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Biological Treatment ◽  
Medical Center ◽  
Biological Agents ◽  
Baseline Serum ◽  
Tertiary Referral Center ◽  
Western Countries ◽  
Before And After ◽  
Inflammatory Bowel

Taiwan has a lower prevalence of inflammatory bowel disease (IBD) and a higher prevalence of tuberculosis (TB) infection than Western countries. The aim of this study was to investigate the prevalence of latent TB (LTB) and active TB infection in IBD patients treated with biological agents. From January 2000 to September 2018, we retrospectively collected data from IBD patients treated with biological agents at a tertiary referral center. Patients underwent a QuantiFERON-TB Gold test (QFT) to screen for TB infection before and after biological treatment courses. The diagnostic age, sex, body mass index, hepatitis B virus infection, biochemistry profile, treatment regimens, and the results of the QFT were analyzed. Overall, 130 IBD patients who received biological treatment were enrolled. The results of the QFT before biological treatment were determined in 120 patients (92%); of these, 10 were positive (8%), 110 were negative (85%), and 10 were indeterminate (9%). Six patients demonstrated seroconversion after biological treatment, as determined by the QFT. Three patients (2.4%) developed active pulmonary TB after biological treatment. In subgroup analysis, the positive QFT patients had a trend of lower baseline serum C-reactive protein and erythrocyte sedimentation rate levels than the negative QFT group. The present study demonstrates that the prevalence of LTB before and after biological treatment is higher in Taiwan than in most Western countries and similar to other Asian countries. Therefore, screening and monitoring of TB infection are necessary for IBD patients before and during biological treatments in Taiwan.

scholarly journals DOP19 Real-world healthcare resource utilisation among patients with inflammatory bowel disease administered vedolizumab for 6 months

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S058-S059
Author(s):  
B Cohen ◽  
H Chang ◽  
J R Jason Rogers ◽  
S Garg ◽  
D Lawrence ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
New York ◽  
Real World ◽  
Bowel Disease ◽  
Healthcare Resource ◽  
Medical Center ◽  
Resource Utilisation ◽  
Healthcare Resource Utilisation ◽  
Inflammatory Bowel

Abstract Background Inflammatory bowel disease (IBD) is associated with high healthcare resource utilisation. Vedolizumab (VDZ) is a gut-selective monoclonal antibody that binds the α4β7 integrin and is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD). We investigated real-world healthcare resource utilisation for these patients in the 6 months after initiating VDZ treatment. Methods This retrospective, non-interventional, cohort study examined healthcare resource utilisation for adults with IBD treated with VDZ at Mt Sinai Medical Center (New York, NY) between June 1, 2014, and May 31, 2019. IBD-related healthcare resource utilisation (emergency room [ER] visits, hospitalisations, procedures, corticosteroids) and VDZ treatment patterns (induction, persistence, adherence) were assessed for 6 months after first VDZ infusion. Discontinuation was defined as a ≥90-day gap between infusions or stopping VDZ treatment <6 months after the first infusion. Patients who had ≥90-day gaps were not counted as discontinuing if they experienced clinical benefit that continued beyond the 6-month period. Results 880 patients treated with VDZ were assessed. Mean age was 39.6 years; 51.6% of patients were female. 369 (41.9%) and 504 (57.3%) patients were diagnosed with CD and UC, respectively. 81.4% of patients received 3 VDZ induction doses by Day 98; 69.0% received 4 doses by Day 120. The rates of ER visits, hospitalisations and elective surgical or urgent hospitalisations and procedures among VDZ-treated patients were <1 per 100 pt–months. Steroids (oral or IV) were prescribed to 42.2% of patients during the 6-month period. In the 2 months after their last infusion, 81.6% of patients who received ≥3 VDZ doses were steroid-free. Timing of the last infusion was variable. Overall VDZ persistence was 68.0% (65.0% and 70.2% for CD and UC, respectively; Figure). Most patients (67.2%) had ≥80% of days covered in a 180-day period Conclusion At a tertiary IBD centre, VDZ was associated with low healthcare resource utilisation during the first 6 months of treatment. More than two-thirds of patients persisted with treatment, with most being steroid-free at last follow-up.

Prevalence of Depression in Patients With Inflammatory Bowel Disease from the Gastroenterologist Service at National Medical Center 20 de Noviembre

2018 ◽  
Vol 113 ◽  
pp. S16-S17
Author(s):  
Yahaira Vicencio Rivera ◽  
Jesús Goméz López ◽  
Roxana Romo Rodriguez ◽  
Tomas Espinosa Cortes ◽  
Mayra Gómez Ramos
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Medical Center ◽  
National Medical ◽  
Prevalence Of Depression ◽  
Inflammatory Bowel

scholarly journals Utilization of Preventive Measures for Glucocorticoid-Induced Osteoporosis among Veterans with Inflammatory Bowel Disease

2013 ◽  
Vol 2013 ◽  
pp. 1-5 ◽  
Author(s):  
Aikaterini Thanou ◽  
Tauseef Ali ◽  
Omar Haq ◽  
Sindhu Kaitha ◽  
Jordan Morton ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Medical Center ◽  
Standard Of Care ◽  
Patient Characteristics ◽  
Physician Education ◽  
Osteoporosis Prevention ◽  
Mineral Density ◽  
Bmd Testing ◽  
Inflammatory Bowel

Purpose. We examined current osteoporosis prevention practices in patients with inflammatory bowel disease (IBD) on chronic steroid using the 2003 American Gastroenterological Association guidelines as standard of care. Methods. We identified all IBD patients followed at the Oklahoma City VA Medical Center from January 2003 to December 2010, who had been on daily oral steroids (prednisone ≥5 mg or budesonide ≥6 mg) for ≥3 consecutive months. Associations of calcium and vitamin D (vitD) prescribing and bone mineral density (BMD) testing with patient characteristics were examined by logistic regression. Results. Sixty-three of 384 consecutive patients met inclusion criteria. Among 86 steroid courses, calcium and vitD were concurrently prescribed in 46%, and BMD was tested in 30%. There was no association of demographic and clinical characteristics with calcium/vitD prescribing and BMD testing. By multivariate analysis, steroid initiation after 2006, compared to before 2006, was associated with a significant increase in calcium (OR = 3.17 and P=0.02) and vitD (OR = 2.96 and P=0.02) prescribing and BMD testing (OR = 4.63 and P=0.004). Conclusions. We observed a low, yet increasing, adherence to osteoporosis prevention guidelines in IBD since 2003, which highlights the need for continued physician education to enhance guideline awareness and implementation.

Sign in / Sign up

Export Citation Format

Share Document